1987
Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.
Dmitrovsky E, Matthews M, Bunn P, Schechter G, Makuch R, Winkler C, Eddy J, Sausville E, Ihde D. Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis. Journal Of Clinical Oncology 1987, 5: 208-15. PMID: 3492594, DOI: 10.1200/jco.1987.5.2.208.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaCytologic transformationCell lymphomaClinical courseClinicopathologic entityCutaneous T-cell lymphoma patientsTumor cell DNA contentT-cell lymphoma patientsAggressive clinical courseDistinct clinicopathologic entityCell lymphoma patientsPeripheral blood smearMalignant T cellsLarge cell lymphomaConvoluted lymphocytesMedian survivalVisceral sitesLymph nodesOccasional patientMedian timeLymphoma patientsPoor prognosisCell DNA contentT cells
1986
Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer.
Brooks B, Seifter E, Walsh T, Lichter A, Bunn P, Zabell A, Johnston-Early A, Edison M, Makuch R, Cohen M. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 200-9. PMID: 3003259, DOI: 10.1200/jco.1986.4.2.200.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Small CellCombined Modality TherapyCyclophosphamideDoxorubicinFemaleHumansLomustineLung NeoplasmsMaleMethotrexateMiddle AgedProcarbazinePrognosisProspective StudiesPulmonary FibrosisRadiographyRandom AllocationRespiratory Function TestsVincristineConceptsPulmonary function testsLimited stage small cell lung cancerStage small cell lung cancerSmall cell lung cancerModality therapyPulmonary toxicityPulmonary complicationsVital capacityLung cancerRadiation therapyLife-threatening pulmonary toxicityInitial pulmonary function testLower vital capacitySubsequent pulmonary complicationsBilateral pulmonary infiltratesDisease-free survivalModality armPulmonary infiltratesPulmonary morbidityExpiratory volumeOverall survivalPerformance statusProspective trialClinical courseHospital admission
1982
Carcinomatous Leptomeningitis in Small Cell Lung Cancer
ROSEN S, AISNER J, MAKUCH R, MATTHEWS M, IHDE D, WHITACRE M, GLATSTEIN E, WIERNIK P, LICHTER A, BUNN P. Carcinomatous Leptomeningitis in Small Cell Lung Cancer. Medicine 1982, 61: 45. PMID: 6276648, DOI: 10.1097/00005792-198201000-00005.Peer-Reviewed Original ResearchConceptsClinical courseSystemic diseaseSpinal cordUnivariate log-rank analysisSmall cell lung cancerProgressive systemic diseaseLog-rank analysisPatient's clinical courseSpinal cord lesionsCell lung cancerVirchow-Robin spacesLife-table analysisCNS metastasesComplete respondersExtensive diseaseIntrathecal chemotherapyLiver metastasesMedian survivalSystemic therapyComplete responseCord lesionsIntracerebral metastasesAutopsy featuresDiffuse involvementSole manifestation
1980
Direct cloning of human neuroblastoma cells in soft agar culture.
Von Hoff D, Casper J, Bradley E, Trent J, Hodach A, Reichert C, Makuch R, Altman A. Direct cloning of human neuroblastoma cells in soft agar culture. Cancer Research 1980, 40: 3591-7. PMID: 7002289.Peer-Reviewed Original ResearchConceptsSoft agar systemNeuroblastoma cellsBone marrowPositive bone marrowHuman neuroblastoma cellsBasic science studiesAgar systemNumber of coloniesMarrow examinationStem cell assayClinical courseLymph nodesPoor prognosisSoft agar cultureTumor responseCatecholamine secretionHistological statusMarrow samplesTumor relapseSoft agar techniquePatientsSolid tumorsPathology studiesCulture resultsNegative specimens
1979
Thymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation of in vitro studies with clinical course
Lipson S, Chretien P, Makuch R, Kenady D, Cohen M. Thymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation of in vitro studies with clinical course. Cancer 1979, 43: 863-870. PMID: 218717, DOI: 10.1002/1097-0142(197903)43:3<863::aid-cncr2820430313>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsTotal T cellsPretreatment CEA levelsT cellsCEA levelsClinical courseCellular immunityTumor responsePretreatment levelsCarcinoembryonic antigenAdministration of thymosinIntensive chemotherapy programsPeripheral blood levelsSmall cell carcinomaDuration of responseOverall tumor responseThymus-dependent lymphocytesLarger patient populationType of treatmentP groupMechanism of actionComplete remissionT60 groupChemotherapy programBronchogenic carcinomaImmune defectsEffects of Thymosin Fraction 5 in Cancer Patients: In Vitro Studies and Correlations with Clinical Course in Patients Receiving Thymosin
Chretien P, Lipson S, Makuch R, Kenady D, Snyder J, Cohen M. Effects of Thymosin Fraction 5 in Cancer Patients: In Vitro Studies and Correlations with Clinical Course in Patients Receiving Thymosin. 1979, 159-166. DOI: 10.1016/b978-0-08-023194-5.50023-1.Peer-Reviewed Original ResearchT cell levelsThymosin fraction 5Cancer patientsClinical coursePatient groupT cellsLow CEA levelWeeks of therapyCell-mediated immunityEffect of thymosinSmall cell carcinomaSuch patient groupsComplete tumor remissionFraction 5Certain serum glycoproteinsSimilar groupsAdjuvant treatmentIntensive chemotherapyImmunologic effectsCEA levelsFurther therapyImmune defectsCellular immunityCell carcinomaTumor remission